---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-035061"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2023-03-21T23:59:59+00:00"
generated_at: "2026-06-17T22:14:38.216912+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TELA Bio Q4 revenue $11.6M (+39% YoY); FY2023 guidance $60-65M

## Summary
- Full-year 2022 revenue $41.4M (+41% YoY); net loss $44.3M.
- Q4 2022 gross margin 70% vs 68% a year ago; cash $42.0M at Dec 31.
- OviTex revenue +26% YoY; OviTex PRS +92% YoY; new NIVIS and OviTex LPR launches.
- FY2023 revenue guidance $60-65M (45-57% growth).

## SEC filing metadata
- accession: 0001104659-23-035061
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2023-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465923035061/0001104659-23-035061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465923035061/tm239776d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-035061
- JSON: https://secwatch.observer/filing/0001104659-23-035061.json
- Plain text: https://secwatch.observer/filing/0001104659-23-035061.txt

## Key facts
- Earnings Releases
  TELA Bio, Inc. reported Full year 2023 results: revenue $60 million to $65 million. Guidance initiated.
  - Period: Full year 2023
  - Revenue: $60 million to $65 million
  - Guidance: initiated
  - Result: guidance update
  source text: Full year 2023 revenue is projected to range from $60 million to $65 million, reflecting growth of 45% to 57% over full year 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465923035061/0001104659-23-035061-index.htm
- Earnings Releases
  TELA Bio, Inc. reported the fourth quarter of 2022 results: revenue $11.6 million, net income $10.0 million.
  - Period: the fourth quarter of 2022
  - Revenue: $11.6 million
  - Net income: $10.0 million
  - Result: reported results
  source text: Revenue was $11.6 million in the fourth quarter of 2022, an increase of 39% compared to the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465923035061/0001104659-23-035061-index.htm
- Earnings Releases
  TELA Bio, Inc. reported the full year ended December 31, 2022 results: revenue $41.4 million, net income $44.3 million.
  - Period: the full year ended December 31, 2022
  - Revenue: $41.4 million
  - Net income: $44.3 million
  - Result: reported results
  source text: Revenue was $41.4 million for the full year 2022, an increase of 41% compared to the full year 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465923035061/0001104659-23-035061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.